HR+/HER2- BREAST CANCER
Clinical trials for HR+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug aims to outsmart Hormone-Resistant breast cancer
Disease control Not yet recruitingThis phase 3 trial compares an experimental drug called BL-B01D1 to standard chemotherapy in people with a common type of breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and cannot be removed by surgery. The study aims to see if BL-B01D1 can delay cancer …
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New dosing strategy aims to help breast cancer patients stick with treatment
Disease control Not yet recruitingThis study tests whether starting abemaciclib at a lower dose and gradually increasing it can reduce early side effects like diarrhea and fatigue in people with high-risk HR+/HER2- breast cancer. The goal is to help more patients stay on their full treatment plan. About 86 partic…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE4 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo therapy aims to control breast cancer brain metastases
Disease control Not yet recruitingThis study tests whether combining brain radiation with a targeted drug (dalpiciclib) and hormone therapy can help control breast cancer that has spread to the brain in people with HR-positive/HER2-negative disease. About 46 participants will receive the combination and be follow…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Gene test may spare young breast cancer patients from chemo
Disease control Not yet recruitingThis study looks at whether a genetic test (Prosigna®) can help decide if younger women with early, hormone-sensitive breast cancer need chemotherapy. About 3380 premenopausal women will either get standard treatment (chemo plus hormone therapy) or a treatment plan based on the t…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to outsmart Drug-Resistant breast cancer
Disease control Not yet recruitingThis study tests whether adding famitinib to SHR-A1811 works better than SHR-A1811 alone for people with a certain type of advanced breast cancer (HR+/HER2-) that no longer responds to CDK4/6 inhibitors. About 248 women aged 18-70 will take part. The goal is to see if the combina…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Tailored drug combo aims to boost breast cancer remission before surgery
Disease control Not yet recruitingThis phase 2 trial tests a personalized approach for women with early-stage HR+/HER2+ breast cancer. After two cycles of standard therapy, patients who respond well continue the same treatment, while those who do not switch to a combination of targeted therapy and hormone-blockin…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Bengbu Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Radiation plus Chemo-Immunotherapy shows promise in High-Risk breast cancer trial
Disease control Not yet recruitingThis study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a common, high-risk breast cancer type (HR+/HER2-). About 302 participants will be randomly assigned to receive either chemo-im…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug combo aims to shrink breast tumors before surgery
Disease control Not yet recruitingThis phase II trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy before surgery can improve tumor response in 30 patients with HR+/HER2- breast cancer. The study uses a two-stage design to check if enough patients achieve a …
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Radiation before surgery: a new hope for tough breast cancers?
Disease control Not yet recruitingThis study tests whether adding radiation before surgery to standard chemotherapy can shrink tumors more effectively in people with locally advanced breast cancer. It includes 50 participants with Luminal or triple-negative subtypes who did not respond well to initial chemo. The …
Matched conditions: HR+/HER2- BREAST CANCER
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 16:14 UTC
-
New questionnaire could let breast cancer patients skip some hospital trips
Symptom relief Not yet recruitingThis study tests a simple home questionnaire for women with HR+HER2- advanced breast cancer who are taking CDK4/6 inhibitors and hormone therapy. The goal is to see if the questionnaire can accurately identify which patients truly need to come to the hospital for a check-up, pote…
Matched conditions: HR+/HER2- BREAST CANCER
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Could chia seeds ease chemo side effects? tiny study aims to find out
Knowledge-focused Not yet recruitingThis study looks at how gut bacteria affect diarrhea and other stomach issues in people with HR+/HER2- breast cancer taking the drug abemaciclib. In the first part, researchers will collect stool samples to track bacteria changes. In the second part, a small group will try eating…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC